Compare Snap Inc (SNAP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs Viatris Inc — how do they compare? Snap Inc trades at $5.31 (market cap $9.18B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 2.1× Snap Inc's market cap, and Viatris Inc pays a 2.89% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| SNAP | VTRS | |
|---|---|---|
Market Cap | $9.18B | $19.09B |
Sector | Media | Health |
52-Week High | $9.09 | $17.86 |
52-Week Low | $3.93 | $9.49 |
Enterprise Value | $10.75B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $5.43, down 0.73% with a bullish technical signal despite recent legal pressures. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M net income). Analyst consensus is mixed with 38% buy ratings and a $7.02 price target, while recent news highlights leadership changes and ongoing youth-safety lawsuits.
Snap presents a turnaround story with operational improvements but faces significant legal and competitive risks. The stock offers potential upside to analyst targets if execution continues, though persistent losses and regulatory challenges warrant caution for investors seeking stability.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
